Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexicon Pharmaceuticals, Inc. - Common Stock (NQ: LXRX )

0.7058 -0.0604 (-7.88%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,407,794
Open 0.7600
Bid (Size) 0.7178 (5)
Ask (Size) 0.7239 (27)
Prev. Close 0.7662
Today's Range 0.6704 - 0.7650
52wk Range 0.6204 - 3.730
Shares Outstanding 144,474,452
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lexicon Appoints Scott Coiante as Chief Financial Officer
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Analyst Expectations For Lexicon Pharmaceuticals's Future
Via Benzinga

Performance

YTD
-9.18%
-9.18%
1 Month
-12.90%
-12.90%
3 Month
-60.57%
-60.57%
6 Month
-66.71%
-66.71%
1 Year
-46.53%
-46.53%

More News

Read More
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
2 Generic Drug Stocks Ready to Surge in 2025
Via MarketBeat
Topics Government Intellectual Property
Exposures Intellectual Property Political Product Safety
Demystifying Lexicon Pharmaceuticals: Insights From 10 Analyst Reviews
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Preview: Lexicon Pharmaceuticals's Earnings
Via Benzinga
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Pharmaceuticals to Participate in December Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Lexicon Appoints Ivan H. Cheung to Board of Directors
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Lexicon Pharmaceuticals Stock
Via Benzinga
The Analyst Verdict: Lexicon Pharmaceuticals In The Eyes Of 8 Experts
Via Benzinga
What You Missed On Wall Street This Past Friday
Via Talk Markets
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
Via Benzinga
Exposures Fossil Fuels
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
Via Benzinga
Analyst Scoreboard: 6 Ratings For Lexicon Pharmaceuticals
Via Benzinga
Dow Jumps 400 Points; US Adds 12,000 Jobs In October
Via Benzinga
Topics Stocks
Exposures US Equities
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
FDA Panel Rejects Lexicon's Zynquista For Type 1 Diabetes
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Deep Dive Into Lexicon Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
Peeling Back The Layers: Exploring Lexicon Pharmaceuticals Through Analyst Insights
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.